Sorafenib in advanced hepatocellular carcinoma

Cited by (1,037)

Items 501–600 of 1,037

1. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
   Stephen Lam Chan, Hui‐Chuan Sun, Yang Xu, Hongmei Zeng, Hashem B. El‐Serag, Jeong Min Lee, Myron Schwartz, Richard S. Finn, Jinsil Seong, Xin Wei Wang et al. · 2025 · The Lancet
2. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
   Xichun Hu, Jun Cao, Wenwei Hu, Changping Wu, Yueyin Pan, Li Cai, Zhongsheng Tong, Shusen Wang, Jin Li, Zhonghua Wang et al. · 2014 · BMC Cancer
3. DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
   Ji‐Liang Li, Richard C.A. Sainson, Chern Ein Oon, Helen Turley, Russell Leek, Helen Sheldon, Esther Bridges, Wen Shi, Cameron Edward Snell, Emma T. Bowden et al. · 2011 · Cancer Research
4. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
   Helen Gharwan, Hunter Groninger · 2015 · Nature Reviews Clinical Oncology
5. Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma
   De‐Chen Lin, Anand Mayakonda, Huy Q. Dinh, Pinbo Huang, Lehang Lin, Xiaoping Liu, Ling‐Wen Ding, Jie Wang, Benjamin P. Berman, Erwei Song et al. · 2017 · Cancer Research
6. Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension
   Jaime Bosch, Juan G. Abraldeṣ, Mercedes Fernández, Juan Carlos García‐Pagán · 2010 · Journal of Hepatology
7. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta‐analysis
   Richard S. Finn, Andrew Xiuxuan Zhu, Wigdan H. Farah, Jehad Almasri, Feras Zaiem, Larry J. Prokop, Mohammad Hassan Murad, Khaled S. Mohammed · 2017 · Hepatology
8. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
   Paola Di Gion, Friederike Kanefendt, Andreas Lindauer, Matthias Scheffler, Oxana Doroshyenko, Uwe Fuhr, Jürgen Wolf, Ulrich Jaehde · 2011 · Clinical Pharmacokinetics
9. Hepatocellular Carcinoma
   HoChong Gilles, Tonora Garbutt, Jasmine Landrum · 2022 · Critical Care Nursing Clinics of North America
10. Review article: the management of hepatocellular carcinoma
    CABRERA, R., NELSON, D. R. · 2010 · Alimentary Pharmacology & Therapeutics
11. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
    Victoria Tovar, Clara Alsinet, Augusto Villanueva, Yujin Hoshida, Derek Y. Chiang, Manel Solé, Swan N. Thung, Susana Moyano, Sara Toffanin, Beatriz Mínguez et al. · 2010 · Journal of Hepatology
12. Radiotherapy Plus Transarterial Chemoembolization for Hepatocellular Carcinoma Invading the Portal Vein: Long-Term Patient Outcomes
    Sang Min Yoon, Young‐Suk Lim, Hyung Jin Won, Jong Hoon Kim, Kang Mo Kim, Han Chu Lee, Young–Hwa Chung, Yung Sang Lee, Sung‐Gyu Lee, Jin‐hong Park et al. · 2011 · International Journal of Radiation Oncology*Biology*Physics
13. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
    Riccardo Antonio Lencioni, Robert Montal, Ferràn Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige et al. · 2017 · Journal of Hepatology
14. Hepatitis B Virus-Associated Hepatocellular Carcinoma
    Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxı̀ · 2022 · Viruses
15. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
    Angela Gauthier, Mitchell Ho · 2012 · Hepatology Research
16. Outcomes and endpoints in trials of cancer treatment: the past, present, and future
    Michelle K. Wilson, Katherine Karakasis, Amit M. Oza · 2014 · The Lancet Oncology
17. GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
    Riccardo Antonio Lencioni, Masatoshi Kudo, Sheng‐Long Ye, Jean–Pierre Bronowicki, X.‐P. Chen, Lucy Dagher, Junji Furuse, J.F. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou et al. · 2013 · International Journal of Clinical Practice
18. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell, Sara Toffanin, Augusto Villanueva, Derek Y. Chiang, Beatriz Mínguez, Laia Cabellos, Radoslav Savić, Yujin Hoshida, Kiat Hon Lim, Pedro Melgar‐Lesmes et al. · 2009 · Journal of Hepatology
19. Tumor thrombus: incidence, imaging, prognosis and treatment
    Keith Bertram Quencer, Tamir Friedman, Rahul A. Sheth, Rahmi Öklü · 2017 · Cardiovascular Diagnosis and Therapy
20. Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress
    Chikara Shirata, Junichi Kaneko, Yoshinori Inagaki, Takashi Kokudo, Masumitsu Sato, Sho Kiritani, Nobuhisa Akamatsu, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa et al. · 2017 · Scientific Reports
21. Viral Oncology: Molecular Biology and Pathogenesis
    U. Mui, Christopher T. Haley, S. Tyring · 2017 · Journal of Clinical Medicine
22. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma
    Carina Hage, Sabine Hoves, Léanne Strauss, Stefan Bissinger, Ylva Prinz, Thomas Pöschinger, Fabian M. Kiessling, Carola Hermine Ries · 2019 · Hepatology
23. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
    Coşkun Özer Demirtaş, Antonio D’Alessio, Lorenza Rimassa, Rohini Sharma, David James Pinato · 2021 · JHEP Reports
24. Hepatic Radiation Toxicity: Avoidance and Amelioration
    Chandan Guha, Brian D. Kavanagh · 2011 · Seminars in Radiation Oncology
25. Epigenetic Regulation of Cancer Stem Cell Marker Cd133 by Transforming Growth Factor-β
    Hanning You, Wei Ding, Bart C. Rountree · 2010 · Hepatology
26. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
    Hung The Huynh, Van Chanh Ngo, Joseph Fargnoli, Mark Ayers, Khee Chee Soo, Heng Nung Koong, Choon Hua Thng, Hock Soo Ong, Alexander Yaw Fui Chung, Pierce K. H. Chow et al. · 2008 · Clinical Cancer Research
27. Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
    Jin Hou, Ye Zhou, Yuanyuan Zheng, Jia Fan, Weiping Zhou, Irene Oi‐Lin Ng, Hui‐Chuan Sun, Lun–Xiu Qin, Shuang‐Jian Qiu, Joyce M.F. Lee et al. · 2013 · Cancer Cell
28. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
    Julie Giraud, Domitille Chalopin, Jean‐Frédéric Blanc, Maya Saleh · 2021 · Frontiers in Immunology
29. Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival
    Ahsun Riaz, Robert K. Ryu, Laura Kulik, Mary F. Mulcahy, Robert J. Lewandowski, Jeet Minocha, Saad Ibrahim, Kent T. Sato, Talia Baker, Frank H. Miller et al. · 2009 · Journal of Clinical Oncology
30. Insights into the success and failure of systemic therapy for hepatocellular carcinoma
    Jordi Bruix, Leonardo Gomes da Fonseca, María Reig · 2019 · Nature Reviews Gastroenterology & Hepatology
31. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
    Bridget P. Keenan, Lawrence H. Fong, Robin Kate Kelley · 2019 · Journal for ImmunoTherapy of Cancer
32. miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
    Jong Kook Park, Takayuki Kogure, Gerard James Nuovo, Jinmai Jiang, Lei He, Ji Hye Kim, Mitch A. Phelps, Tracey L. Papenfuss, Carlo Maria Croce, Tushar C. Patel et al. · 2011 · Cancer Research
33. Chemoembolization of Hepatocellular Carcinoma
    P Petruzzi, Laura Crocetti, Riccardo Antonio Lencioni · 2013 · Seminars in Interventional Radiology
34. Neutrophils as potential therapeutic targets in hepatocellular carcinoma
    Daniel Geh, Jack Leslie, Rob Rumney, Helen Louise Reeves, Thomas Graham Bird, Derek A. Mann · 2022 · Nature Reviews Gastroenterology & Hepatology
35. Antiangiogenic Therapy for Cancer: An Update
    Belal A. Al-Husein, Maha Abdalla, Morgan Trepte, David L. DeRemer, Payaningal R. Somanath · 2012 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
36. Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
    Gideon Michael Blumenthal, Stella Wanjugu Karuri, Hui Zhang, Lijun Zhang, Sean Khozin, Dickran Gano Kazandjian, Shenghui W. Tang, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur · 2015 · Journal of Clinical Oncology
37. Hepatocellular carcinoma in the era of immunotherapy
    Hao‐Wen Sim, Jennifer Jane Knox · 2017 · Current Problems in Cancer
38. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
    Zobair M. Younossi, Linda L Henry · 2021 · JHEP Reports
39. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
    Carmelo Bengala, Federica Bertolini, N. Malavasi, Corrado Boni, Enrico Aitini, Cristina Dealis, Sandra Zironi, Roberta Depenni, Annalisa Fontana, Cinzia Del Giovane et al. · 2009 · British Journal of Cancer
40. Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
    Fabio A.B. Schutz, Youjin Je, Christopher J. Richards, Toni K. Choueiri · 2012 · Journal of Clinical Oncology
41. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Richard S. Finn, Yoon‐Koo Kang, Mary F. Mulcahy, Blasé N. Polite, Ho Yeong Lim, Ian B Walters, Christine Baudelet, Demetrios Manekas, Joong‐Won Park · 2012 · Clinical Cancer Research
42. Genome-Wide Methylation Analysis and Epigenetic Unmasking Identify Tumor Suppressor Genes in Hepatocellular Carcinoma
    Kate Revill, Tim Wang, Anja Lachenmayer, Kensuke Kojima, Andrew Harrington, Jinyu Li, Yujin Hoshida, Josep Maria Llovet, Scott Powers · 2013 · Gastroenterology
43. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling
    Juan Chen, Anthony W.H. Chan, Ka‐Fai To, Weixian Chen, Zhenzhen Zhang, Ji‐Hua Ren, Chunli Song, Yue S. Cheung, Paul B.S. Lai, Suk‐Hang Cheng et al. · 2013 · Hepatology
44. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
    Changjun He, Xuesong Dong, Bo Zhai, Xian Li Jiang, Deli Dong, Baoxin Li, Hongchi Jiang, Shidong Xu, Xueying Sun · 2015 · Oncotarget
45. Recent advances in systemic therapy for hepatocellular carcinoma
    Huajun Zhang, Wuyang Zhang, Longying Jiang, Yongheng Chen · 2022 · Biomarker Research
46. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
    Cheng Sun, Haoyu Sun, Weihua Xiao, Cai Zhang, Zhigang Tian · 2015 · Acta Pharmacologica Sinica
47. Epidemiology and Management of Hepatocellular Carcinoma
    Ju Dong Yang, Lewis Rowland Roberts · 2010 · Infectious Disease Clinics of North America
48. Survival comparison between glioblastoma multiforme and other incurable cancers
    Ben Tran, Mark Andrew Rosenthal · 2010 · Journal of Clinical Neuroscience
49. Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Hans‐Joachim Schmoll, David Cunningham, Alberto Felice Sobrero, Christos Stelios Karapetis, Philippe R Rougier, Sheryl L. Koski, Ilona Kocáková, Igor Bondarenko, Gyorgy Bodoky, Paul N. Mainwaring et al. · 2012 · Journal of Clinical Oncology
50. Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
    Weijing Sun, Mark E. Powell, Peter James O'Dwyer, Paul J. Catalano, Rafat Ansari, Al B. Benson · 2010 · Journal of Clinical Oncology
51. Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy
    Mija Marinković, Matilda Šprung, Maja Buljubašić, Ivana Novak · 2018 · Oxidative Medicine and Cellular Longevity
52. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update
    Ningyuan Wen, Yulong Cai, Fu‐Yu Li, Hui Ye, Wei Tang, Peipei Song, Nansheng Cheng · 2022 · BioScience Trends
53. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
    Alessandro Vitale, Patrizia Burra, Anna Chiara Frigo, Franco Trevisani, Fabio Farinati, Gaya Spolverato, Michael L. Volk, Edoardo Giovanni Giannini, Francesca Ciccarese, Fabio Piscaglia et al. · 2014 · Journal of Hepatology
54. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
    Sang Hun Lee, Dongjun Jeong, Yong‐Seok Han, Moo Jun Baek · 2015 · Annals of Surgical Treatment and Research
55. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in mice
    Yunching Chen, Yuhui Huang, Thomas Reiberger, Annique M. M. J. Duyverman, Peigen Huang, Rekha Samuel, Lotte Hiddingh, Sylvie Roberge, Christina Koppel, Gregory Yves Lauwers et al. · 2013 · Hepatology
56. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
    Nicola Personeni, Silvia Bozzarelli, Tiziana Pressiani, Lorenza Rimassa, Maria Chiara Tronconi, Francesco Sclafani, Carlo Carnaghi, Vittorio Pedicini, Laura Giordano, Armando Santoro · 2012 · Journal of Hepatology
57. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers
    Catharine M. Sturgeon, Michael Joe Duffy, Barry R Hofmann, R. Lamerz, Herbert A. Fritsche, Katja N. Gaarenstroom, Johannes M.G. Bonfrèr, Thorsten Ecke, Herbert Barton Grossman, Peter Clive Hayes et al. · 2010 · Clinical Chemistry
58. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma
    Yuanjun Lu, Yau-Tuen Chan, Hor‐Yue Tan, Cheng Zhang, Wei Guo, Yu Xu, Rakesh Sharma, Zhe‐Sheng Chen, Yi‐Chao Zheng, Ning Wang et al. · 2022 · Journal of Experimental & Clinical Cancer Research
59. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Qian Zhou, Vivian Wai Yan Lui, Winnie Yeo · 2011 · Future Oncology
60. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
    Tim F. Greten, Alejandro Forner, Firouzeh Korangy, G. Nkontchou, Nathalie Barget, Carmen Ayuso, Lars A. Ormandy, Michael Peter Manns, Michel Beaugrand, Jordi Bruix · 2010 · BMC Cancer
61. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
    Minke He, Run-Bin Liang, Yang Zhao, Yu-Jie Xu, Huanwei Chen, Yuan-Min Zhou, ZhiCheng Lai, Li Xu, Wei Wei, Yaojun Zhang et al. · 2021 · Therapeutic Advances in Medical Oncology
62. Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities
    Jonathan Klein, Laura Ann Dawson · 2012 · International Journal of Radiation Oncology*Biology*Physics
63. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
    Renumathy Dhanasekaran, Jean‐Charles Nault, Lewis Rowland Roberts, Jessica Zucman‐Rossi · 2018 · Gastroenterology
64. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
    J. Nault, Yoann Martin, S. Caruso, T. Hirsch, Q. Bayard, J. Calderaro, C. Charpy, C. Copie-Bergman, M. Ziol, P. Bioulac-Sage et al. · 2020 · Hepatology
65. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas
    Xiaofan Ding, Mian He, Anthony W.H. Chan, Qi Xiu Song, Siu Ching Sze, Hui Chen, K Man, Kwan Man, Stephen Lam Chan, Paul B.S. Lai et al. · 2019 · Gastroenterology
66. Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study
    Anne-Laure Hermann, Arnaud Dieudonné, Maxime Ronot, Manuel Sánchez-García, Héléna Pereira, Gilles Châtellier, Étienne Garin, Laurent Castéra, Rachida Lebtahi, Valérie Vilgrain et al. · 2020 · Radiology
67. Rational Design of a Highly Selective Near‐Infrared Two‐Photon Fluorogenic Probe for Imaging Orthotopic Hepatocellular Carcinoma Chemotherapy
    Xiaofeng Wu, Rui Wang, Sujie Qi, Nahyun Kwon, Jingjing Han, Heejeong Kim, Haidong Li, Fabiao Yu, Juyoung Yoon · 2021 · Angewandte Chemie International Edition
68. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
    Tadaaki Arizumi, Kazuomi Ueshima, Tomohiro Minami, Masashi Kono, Hirokazu Chishina, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Norihisa Yada, Satoru Hagiwara et al. · 2015 · Liver Cancer
69. Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal
    Franco Trevisani, Marta Frigerio, Valentina Santi, Alice Grignaschi, Mauro Bernardi · 2009 · Digestive and Liver Disease
70. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
    Anja Lachenmayer, Sara Toffanin, Laia Cabellos, Clara Alsinet, Yujin Hoshida, Augusto Villanueva, Beatriz Mínguez, Hung Wen Tsai, Stephen C. Ward, Swan N. Thung et al. · 2012 · Journal of Hepatology
71. Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
    Sònia Tugues, Sina Koch, Laura Gualandi, Xiujuan Li, Lena Claesson · 2011 · Molecular Aspects of Medicine
72. Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
    Antonius Arthur Miller, Daryl J. Murry, Kouros Owzar, Donna R. Hollis, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Apurva A. Desai, Jimmy J. Hwang, Miguel Angel Villalona-Calero, E. Claire Dees et al. · 2009 · Journal of Clinical Oncology
73. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
    Victoria Tovar, Helena Cornellà, Agrin Moeini, Samuel J. Vidal, Yujin Hoshida, Daniela Sia, Judit Peix, Laia Cabellos, Clara Alsinet, Sara Torrecilla et al. · 2015 · Gut
74. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
    Xingliang Guo, Hua Jiang, Bizhi Shi, Min Zhou, Honghong Zhang, Zhimin Shi, Guoxiu Du, Hong Luo, Xiuqi Wu, Yi Wang et al. · 2018 · Frontiers in Pharmacology
75. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma
    Lee Jin Lim, Samuel Yeung Shan Wong, Feiyang Huang, Sheng Lim, Samuel S. Chong, London Lucien Ooi, Oi Lian Kon, Caroline Guat Lay Lee · 2019 · Cancer Research
76. Ketamine Induces Ferroptosis of Liver Cancer Cells by Targeting lncRNA PVT1/miR-214-3p/GPX4
    Guannan He, Naren two ya Bao, Shuang Wang, Man Xi, Tian-Hao Zhang, Fengshou Chen · 2021 · Drug Design Development and Therapy
77. Engineering Melanin Nanoparticles as an Efficient Drug–Delivery System for Imaging‐Guided Chemotherapy
    Ruiping Zhang, Quli Fan, Min Yang, Kai Cheng, Xiaomei Lü, Lei Zhang, Wei Huang, Zhen Cheng · 2015 · Advanced Materials
78. GLUT1 as a therapeutic target in hepatocellular carcinoma
    Thomas Amann, Claus Hellerbrand · 2009 · Expert Opinion on Therapeutic Targets
79. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma
    Anupam Bishayee, Themos Politis, Altaf S. Darvesh · 2009 · Cancer Treatment Reviews
80. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: Current understanding and future directions
    Garrick K. Wilson, Daniel A. Tennant, Jane A. McKeating · 2014 · Journal of Hepatology
81. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
    George R. Blumenschein, Ulrich Gatzemeier, Frank V. Fossella, David J. Stewart, Lisa Cupit, Frank Cihon, James O'Leary, Martin Reck · 2009 · Journal of Clinical Oncology
82. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
    Jian Lü, Xiuping Zhang, Bin‐Yan Zhong, Wan Yee Lau, David C. Madoff, Jon C. Davidson, Xiaolong Qi, Shuqun Cheng, Gao‐Jun Teng · 2019 · The Lancet. Gastroenterology & hepatology
83. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
    Fabian Finkelmeier, Özge Canli, Andrea Oliver Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten et al. · 2016 · European Journal of Cancer
84. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
    Xiangyuan Luo, Kongming Wu, Xingxing He · 2021 · Journal of Experimental & Clinical Cancer Research
85. A Pharmacogenomic Landscape in Human Liver Cancers
    Zhixin Qiu, Hong Li, Zhengtao Zhang, Zhenfeng Zhu, Sheng He, Xujun Wang, Pengcheng Wang, Jianjie Qin, Liping Zhuang, Wei Wang et al. · 2019 · Cancer Cell
86. Immune-based therapies for hepatocellular carcinoma
    David James Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco Angelo Mauri, Sujit K. Mukherjee, Mark R. Thursz, Ching Ngar Wong, Rohini Sharma et al. · 2020 · Oncogene
87. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
    Ole‐Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin, Rana R. McKay, Lipika Goyal, Michael E Davis, Marina Dusevic Kaymakcalan, Jonathan S. Williams · 2014 · Cancer
88. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
    Y-C Shen, Da‐Liang Ou, Chiun Hsu, K-L Lin, C-Y Chang, C-Y Lin, Shing‐Hwa Liu, A-L Cheng · 2012 · British Journal of Cancer
89. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
    Beom Kyung Kim, Seung Up Kim, Kyung Ah Kim, Yong Eun Chung, Myeong‐Jin Kim, Mi‐Suk Park, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Man Deuk Kim et al. · 2015 · Journal of Hepatology
90. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells
    Tai, W-T, Shiau, C-W, Chen, H-L, Liu, C-Y, Lin, C-S, Cheng, A-L, Chen, P-J, Chen, K-F · 2013 · Cell Death & Disease
91. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma
    Grace L. Su, Osama Altayar, Robert O’Shea, Raj Shah, Bassam N. Estfan, Candice M. Wenzell, Shahnaz Sultan, Yngve T Falck-Ytter · 2022 · Gastroenterology
92. Surgical and Locoregional Therapy of HCC: TACE
    Masakatsu Tsurusaki, Takamichi Murakami · 2015 · Liver Cancer
93. The Significance of Classifying Microvascular Invasion in Patients with Hepatocellular Carcinoma
    Shuji Sumie, Osamu Nakashima, Koji Okuda, Ryoko Kuromatsu, Atsushi Kawaguchi, Masahito Nakano, Manabu Satani, Shingo Yamada, Shusuke Okamura, Maisa Hori et al. · 2013 · Annals of Surgical Oncology
94. 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma
    Korean Liver Cancer Study Group (KLCSG) · 2015 · Korean Journal of Radiology
95. Tumor-Associated Macrophages as Target for Antitumor Therapy
    Katarzyna Sawa-Wejksza, Martyna Kandefer‐Szerszeń · 2017 · Archivum Immunologiae et Therapiae Experimentalis
96. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
    Chun‐Hao Huang, Amaia Lujambio, Johannes A. Zuber, Darjus Felix Tschaharganeh, Michael G. Doran, Michael J. Evans, Thomas M. Kitzing, Nan Zhu, Elisa de Stanchina, Charles L. Sawyers et al. · 2014 · Genes & Development
97. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
    Winnie Yeo, Hyun Cheol Chung, Stephen Lam Chan, Ling Z. Wang, Robert S. C. Lim, Joel Picus, Michael Joseph Boyer, Frankie K. F. Mo, Jane Koh, Sun Young Rha et al. · 2012 · Journal of Clinical Oncology
98. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway
    Kung-Chun Chiu, David, Pui-Wah Tse, Aki, Law, Cheuk-Ting, Ming-Jing Xu, Iris, Lee, Derek, Chen, Mengnuo, Kit-Ho Lai, Robin, Wai-Hin Yuen, Vincent, Wing-Sum Cheu, Jacinth, Wai-Hung Ho, Daniel et al. · 2019 · Cell Death & Disease
99. Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice
    Jessica Hiu Tung Lo, Eunice Yuen-Ting Lau, Rachel Hiu Ha Ching, Bowie Yik-Ling Cheng, Mark Kin Fai Ma, Irene Oi‐Lin Ng, Terence K. Lee · 2015 · Hepatology
100. Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
     Romain Coriat, Carole Nicco, Christiane Chéreau, Olivier Mir, Jérôme Alexandre, Stanislas Ropert, Bernard J. Weill, Stanislas Chaussade, François Goldwasser, Frédéric Batteux · 2012 · Molecular Cancer Therapeutics